Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q1 2016 · 10-Q
Revenue—
Net Income-$5.36M-$5.36MN/M vs Q1 2015 EPS Diluted-$0.19-$0.19N/M vs Q1 2015 Operating Income-$5,705,330N/M Operating Cash Flow-$3,319,866N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,322,750N/M ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end